Electromed (ELMD) Proxy filing summary

Executive summary

• Annual Meeting scheduled for November 13, 2026, will be held virtually to enhance shareholder access and participation.

• Shareholders will vote on director elections, auditor ratification, executive compensation, and an employee stock purchase plan.

• Strategic growth drivers include sales force expansion, increased brand awareness, market development, and best-in-class support.

Voting matters and shareholder proposals

• Four main proposals: election of seven directors, ratification of RSM US LLP as auditor for fiscal 2027, advisory approval of executive compensation, and approval of the Employee Stock Purchase Plan (ESPP).

• Board recommends voting FOR all proposals.

• Shareholder proposals for the 2027 meeting must be submitted by June 1, 2027, for inclusion in proxy materials.

• Director nominations for 2027 must be submitted between July 16 and August 15, 2027.

Board of directors and corporate governance

• Seven director nominees, all with significant experience in healthcare, finance, and business management.

• Board structure separates Chair and CEO roles to promote independent oversight.

• All directors except the CEO are considered independent under NYSE American rules.

• Board committees include Audit, Personnel and Compensation, and Nominating and Governance; Finance and Strategy Committee dissolved as of June 30, 2026.

• Directors are encouraged to attend annual meetings; all attended in 2025.